Want to create an interactive transcript for this episode?
Podcast: Foundation Fighting Blindness
Episode: News | FDA Approves Genentech’s Susvimo for Treating Wet AMD
Description: The US Food & Drug Administration (FDA) has approved Susvimo, Genentech’s port delivery system (PDS) with ranibizumab, for the treatment of wet age-related macular degeneration (AMD). The PDS, a refillable capsule the size of a rice grain, provides continual release of ranibizumab, a protein that blocks the growth of vision-robbing, leaky blood vessels which are the hallmark of wet AMD. The PDS is implanted at the surface of the eye during a one-time, outpatient, surgical procedure. The PDS may be refilled as infrequently as twice a year. Susvimo will be available to patients in the coming months.